期刊文献+

我院41例万古霉素血药浓度监测与临床用药分析 被引量:31

Clinical Utilization and Blood Concentration Monitoring of Vancomycin in Our Hospital:Analysis of 41 Cases
原文传递
导出
摘要 目的:评价我院万古霉素血药浓度监测及其临床应用情况。方法:采用回顾性调查方法,对我院2005年11月~2008年12月应用万古霉素并监测血药浓度的41例住院患者的临床资料(基础疾病、细菌学培养结果、万古霉素血药浓度值、疗效、肾功能情况等)进行统计、分析。结果:我院住院患者应用万古霉素的总有效率为65.0%;万古霉素血药浓度所测得峰值<25mg.L-1者占62.7%,谷值<5mg.L-1者占55.2%;治疗后肾功能异常发生率为12.2%。结论:我院住院患者万古霉素应用量和血药浓度均偏低,需重视其血药浓度监测并结合临床实际,实现个体化给药。 OBJECTIVE:To evaluate clinical utilization and blood concentration monitoring of vancomycin in our hospital. METHODS: By retrospective survey method, the clinical information (primary diseases, bacteriological culture, blood concentration of vancomycin, clinical efficacy, renal function) of 41 inpatients who had been treated with vancomycin and their blood concentrations from Nov. 2005 to Dec. 2008 were analyzed statistically. RESULTS: The total response rate of vancomycin was 65.0%. The peak concentration of 62.7% cases were below 25 mg·L-1 while the valley value of 55.2% cases were below 5 mg·L-1. The incidence of renal dysfunction after treatment was 12.2%. CONCLUSION: The consumption and blood concentrations of vancomycin are close to low level in our hospital. It should be paid attention to the blood concentration monitoring of vancomycin to achieve an ideal individual administration according to clinical practice.
出处 《中国药房》 CAS CSCD 北大核心 2010年第26期2430-2432,共3页 China Pharmacy
关键词 万古霉素 血药浓度监测 临床用药 Vancomycin Blood concentration monitoring Clinical use of drugs
  • 相关文献

参考文献5

二级参考文献58

  • 1陈民钧.美国临床实验室标准化委员会2004年版有关药敏试验标准化更新要点[J].中华检验医学杂志,2004,27(9):608-610. 被引量:76
  • 2张新妹,马越,胡昌勤,金少鸿.细菌耐药性调查研究应注意的若干问题[J].中国药房,2005,16(8):624-626. 被引量:10
  • 3马骢,郝秀红,蒋学兵,韩善桥,齐勇志.2170株革兰阳性球菌对临床常用抗菌药物的耐药性监测[J].中华医院感染学杂志,2005,15(7):827-829. 被引量:17
  • 4JONES M E,VISSER M R,KLOOTWIJK M,et al.Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, lfloxacin, sparfloxacin, and trovafloxacin and nonquinoloones linozelid, quinupristin/dalfopritin, gentamicin, and vancomycin agains
  • 5DREW R H,PERFECT K,SRINATH L,et al.Treatment ofmethicillin-resistant Staphylococcus aureus infections with quinupristin/dalfopritin in patients intolerant of or failing prior therapy[J].J Antimicrob Chemother,2000,46(3):775-784.
  • 6REZENDE N A,BLUMVERG H M,METZGER B Z,et al.Risk factors for methicillin-resistance among patients with Staphylococcus aureus bacteremia at the time of hospital admission[J]. Am J Med Sci,2002,323(3):117-123.
  • 7SOULI M,KOPSINIS G,KAVOUKLIS E,et al.Vancomycin levels in human aqueous humour after intravenous and subconjunctival administration[J]. Int J Antimicrob Agents,2002,18(2):239-243.
  • 8NOSKIN G A.Methicillin-resistant staphylococcus aureus and vancomycin-resistant enterococci:Emerging problems and new prospects for management[J]. Annals Academy of Medicine,2001,30(3):320-331.
  • 9RYBAK M J.Therapeutic options for Gram-positive infections[J].J Hosp Infect,2001,49(Suppl A):S25-S32.
  • 10MIYATA A,ARAAKE M,OGAWA H,et al.Effect of arbekacin on the production of toxic shock syndrome toxin 1 by methicillin-resistant Staphylococcus aureus[J].Jpn J Antibiot,2001,54(7):372-381.

共引文献54

同被引文献141

引证文献31

二级引证文献170

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部